Propanc Biopharma, Inc. (PPCB): Long-Term Debt
$537.9K
As of 2025-06-30
$55.0K
As of 2026-03-31
-16.6%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $537.9K | +34.7% | 2025-09-29, Balance as of period end |
| 2024-06-30 | $399.3K | +2.2% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $390.5K | -57.8% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $926.4K | n/c | 2023-09-28, Balance as of period end |
| 2021-06-30 | $624.6K | -59.9% | 2022-09-28, Balance as of period end |
| 2020-06-30 | $1.56M | -6.0% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $1.66M | -64.7% | 2020-10-01, Balance as of period end |
| 2018-06-30 | $4.70M | +35.0% | 2019-10-15, Balance as of period end |
| 2017-06-30 | $3.48M | +189.4% | 2018-09-17, Balance as of period end |
| 2016-06-30 | $1.20M | n/a | 2017-09-28, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $537.9K | +34.7% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $2.12M | n/a |
| Clene Inc. (CLNN) | 2025-12-31 | $17.79M | n/a |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $27.13M | -6.3% |
| Tempest Therapeutics, Inc. (TPST) | 2024-12-31 | $6.40M | -39.0% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $401.0K | -8.6% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $10.00M | n/a |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $38.34M | -15.5% |
Compare PPCB, MENS, CLNN, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗